Loading patent…
AssigneesThe Genetics Company, Inc., Miles Inc.
InventorsAnthony W. Siadak, Mark E. Lostrom
Estimating the term…
Transformed human lymphocyte cell lines have been produced which secrete human monoclonal antibodies to serotypic determinants on LPS molecules of gram-negative bacteria. These antibodies have been found to be protective against lethal challenges of the homologous bacteria. Pharmaceutical compositions containing these antibodies and their prophylactic and therapeutic use in the management of gram-negative disease in humans are also disclosed. Human lymphocyte cell lines secreting human monoclonal antibodies specifically reacting with Pseudomonas aeruginosa Fisher immunotypes 1 (C5B7), 2 (6F11), 4 (C5D5), 5 (13C1), 6 (5G2) and 7 (8E7) were deposited at the American Type Culture Collection and given A.T.C.C. Accession Nos. CRL 8753, CRL 8562, CRL 8754, CRL 8796, CRL 8797 and CRL 8795, respectively.
A protective human monoclonal antibody specifically binding with a serotypic determinant on the accessible lipopolysaccharide molecules of a Pseudomonas aeruginosa bacterium.
A composition comprising at least two protective human monoclonal antibodies, each of said monoclonal antibodies binding with serotypic determinant on the lipopolysaccharide molecules of different Pseudomonas aeruginosa bacteria, wherein said monoclonal antibodies are present at concentrations greater than naturally occurring in human sera.
An immortal transformed human lymphocyte cell line which secretes a protective human monoclonal antibody specifically binding with a serotypic determinant on the accessible lipopolysaccharide molecules of a Pseudomonas aeruginosa bacterium.
Dependencies are inferred from the claim text.